Cormedix Inc. · NASDAQ:CRMD
Cormedix — CorMedix Therapeutics — Investor Presentation (May 2026)
24 slides from Cormedix's investor presentation, May 2026
Slide 1: CorMedix Therapeutics Corporate Presentation
CorMedix Therapeutics Corporate Presentation May 2026 NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act of 1934, as amended (the “Exchange Act”), that are subject to risks and uncertainties.
Slide 3: Introduction
Introduction 3 NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS
Slide 4: CorMedix Therapeutics is a commercial pharmaceutical company for institutional markets
CorMedix Therapeutics is a commercial pharmaceutical company focused on providing innovative products for institutional markets has a diversified portfolio of specialty injectable therapies that is built upon a scalable commercial platform Attractive Financial Profile Diversified Growth Drivers Scal
Slide 5: Proven leadership team with long track record of commercial outperformance
CorMedix Therapeutics has a proven leadership team with a long track record of commercial outperformance JO INED CO RM EDIX T HER AP E UT ICS PRIO R EXPERIEN CE • Chief Commercial Officer of Amneal Specialty Joe Todisco 2022 • Co-founder and Chief Executive of Gemini Laboratories Chairman & Chief Ex
Slide 6: Financial highlights
Financial highlights Key Statistics at March 31, 2026 Balance Sheet at March 31, 2026 Exchange NASDAQ Global Market Cash and short-term investments** $178 million Common Shares Outstanding* 78.5 million Convertible Debt $150 million Key Financials Guidance FY 2025 Net Revenue (Pro Forma1) $401 milli
Slide 7: The combined portfolio consists of a diversified and complementary set of assets
The combined portfolio consists of a diversified and complementary set of assets Shared Call Points Product Current Therapeutic Area Product Class Taurolidine and heparin catheter CRBSI lock solution Hospitals & IDNs Candidemia and invasive candidiasis Echinocandin antifungal Serious infections incl
Slide 8: Our Products
Our Products 8 NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS
Slide 9: DefenCath positioned to capture value across outpatient and inpatient markets
DefenCath is well positioned to capture significant value across both outpatient and inpatient markets DefenCath launched full scale for hemodialysis in July 2024 2H 2026 / 2027 Market Access Strategy TDAPA Buy & Bill Bundle Add-on Strong commercial uptake with commercial agreements in place with
Slide 10: DefenCath first and only FDA-approved catheter lock solution reducing CRBSI
DefenCath is the first and only FDA-approved catheter lock solution with significant risk reduction in catheter-related bloodstream infections (CRBSI) CRBSIs result in significant patient morbidity, mortality, and cost to healthcare systems demonstrated significant reduction in ~2x more hospitalizat
Slide 11: DefenCath – US Renal Care positive real world evidence interim results
DefenCath – US Renal Care positive real world evidence interim results Design Retrospective analysis of outpatients receiving dialysis through a CVC at USRC • 23,663 patients in pre-intervention (July 1, 2022 – June 30, 2024) • 7,051 patients that received at least one dose of DefenCath (July 1, 202
Slide 12: REZZAYO – Product overview
REZZAYO – Product overview REZZAYO disrupts the standard of care of daily echinocandins with its once-weekly dosing schedule, highly simplifying management of candidemia and invasive candidiasis Next generation echinocandin with once-weekly dosing schedule – highly simplifies management of candidemi
Slide 13: MINOCIN, VABOMERE, and the ORI franchise are differentiated anti-infectives
MINOCIN, VABOMERE, and the ORI franchise (KIMYRSA/ORBACTIV) are highly differentiated anti-infectives with IP coverage • Achieved ~$39MM revenue in 2024 • Achieved ~$20MM revenue in 2024 • Differentiated triple MOA that treats & ~$47MM revenue in 2025 & ~$26MM revenue in 2025 ABSSSI caused by gram-p
Slide 14: Expansion & Growth Opportunities
Expansion & Growth Opportunities 14 NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS
Slide 15: Well positioned to create value as a diversified specialty pharma business
CorMedix Therapeutics is well positioned to continue to create value as a diversified specialty pharma business with a compelling growth path Diversified Commercial Leader High-Growth, Cash Flow Generating Operating at Scale Business Inflecting Commercial-Stage Platform for Full Suite of Ongoing Ph
Slide 16: Development stage pipeline has potential to drive value
CorMedix Therapeutics development stage pipeline has potential to drive meaningful value over coming years Pipeline and Growth Opportunities Therapeutic Area Ph III / Product Pre-Clinical Ph I Ph II Commercial Expansion Registrational Prophylaxis* Ph III Topline data announced 4/27/26 Pneumocystis P
Slide 17: ReSPECT Ph 3 study for prophylaxis of invasive fungal infections
Expanded indication Ph 3 study (ReSPECT) for prophylaxis of invasive fungal infections recently completed ReSPECT Ph III Global Multicenter Study • Study for the prevention of invasive fungal diseases in subjects undergoing allogeneic blood and marrow transplantation (BMT) • Primary Endpoint • 13-we
Slide 18: ReSPECT study met its primary endpoint of non-inferiority
ReSPECT study met its primary endpoint of non-inferiority and demonstrated a favorable profile in safety related secondary endpoints Primary Endpoint Comparable Efficacy Rezafungin met primary endpoint of non- Comparable efficacy against invasive infections from Candida, inferiority to standard anti
Slide 19: REZZAYO Prophy – Commercial Opportunity, >$2B TAM
REZZAYO Prophy – Commercial Opportunity REZZAYO’s label expansion into prophylaxis could unlock an opportunity of an additional addressable market representing a >$2B TAM Prophylaxis Addressable Patient Population Growth Opportunity Allo Auto AML SOT Other ~$1.4B Expands portfolio and reach into $50
Slide 20: NUTRI-LOCK Ph 3 study for CLABSIs in adult TPN patients
Expanded indication Ph 3 study (NUTRI-LOCK) for CLABSIs in adult TPN patients is underway Program Overview: A Ph 3, randomized, double-blind, adaptive, 2-arm, study assessing the safety and efficacy of DefenCath in reducing central line-associated bloodstream infections (CLABSIs) in adult patients r
Slide 21: DefenCath in Total Parenteral Nutrition
DefenCath In Total Parenteral Nutrition TPN represents an opportunity of ~4.7MM infusions per year across outpatient and inpatient settings, an addressable market of ~$500-750MM US Total Parenteral Nutrition Total Addressable Market Patient Characterization (2024E) 4 3.64 0.51 Ports or IVs Total Inf
Slide 22: Strong financial flexibility to pursue business development opportunities
CorMedix Therapeutics has strong financial flexibility to pursue business development opportunities Strong Cash Position Strategic Investment in CorMedix Therapeutics as of March 31, 2026 has a In 2025, CorMedix Therapeutics made a strategic strong cash position consisting of ~$178MM of cash investm
Slide 23: Anticipated company milestones
Anticipated company milestones 2026 / 1H 2027 • Additional REZZAYO prophylaxis study data • Medicare Advantage updates • CorMedix Therapeutics earnings and business updates • REZZAYO prophylaxis sNDA submission and potential approval • CMS updates for 2027 add-on payments for FFS patients • Addition
Slide 24: CorMedix Therapeutics key highlights
CorMedix Therapeutics key highlights Commercial specialty pharma business with portfolio of products, revenue scale, and a 1 dynamic commercial platform in acute care poised for organic and inorganic growth 2 Portfolio of differentiated hospital and acute care products 3 DefenCath launch has been su
CorMedix Therapeutics — Investor Presentation (May 2026) on 6ix